Maxipass

Tamsulosin Hydrochloride

Method of action: Alpha-Adrenergic Blocking, Alpha-Adrenolytic, Antidisuric, Normalizing The Function Of The Prostate, Urologicals

Treatment option: Benign Prostatic Hyperplasia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxipass

This section provides a definitive identity and classification for Maxipass (Tamsulosin Hydrochloride), establishing its composition, pharmacological type, and general functional purpose.

Property	Description
Active Ingredient	Tamsulosin Hydrochloride
Form	Modified-release Oral Capsule
Pharmacological Class	Selective Alpha-adrenergic Receptor Antagonist (Alpha Blocker)
General Purpose	Improving Urinary Flow
Origin	Synthetic (sulfonamide-related compound)

What is Maxipass and How is it Classified?

Maxipass is a specific, prescription-only brand of medicine containing the active compound Tamsulosin Hydrochloride. It is classified as a Selective Alpha-adrenergic Receptor Antagonist, belonging to the family of Alpha Blockers. This synthetic drug is defined by its precise targeting of the alpha1A and alpha1D receptor subtypes in the body, a specificity that is clinically recognized for differentiating it from older, less-selective agents. The compound's chemical structure is chemically related to the sulfonamides class, establishing its origin.

Composition and The Modified-Release Form

The therapeutic agent, Tamsulosin Hydrochloride, is formulated for oral administration as a Modified-release Capsule, which is a key differentiating feature of Maxipass. This formulation is also known as a sustained-release formulation, making the product a single-component medicine. This specialized capsule design is crucial because it controls the rate at which the Tamsulosin is absorbed, maintaining a steady, consistent concentration over a full 24-hour cycle. The modified-release approach provides continuous pharmacological activity, which is essential for managing persistent conditions. The sustained-release nature helps ensure the medicine works smoothly throughout the day and night.

General Purpose and Functional Benefit

The general purpose of Maxipass is to deliver functional relief by managing muscle tension within the lower urinary tract. Tamsulosin Hydrochloride accomplishes this by inducing physiological relaxation of the smooth muscles predominantly found in the prostate gland and the neck of the bladder. By decreasing internal resistance on the urethra (the urinary passageway), the drug’s ultimate functional benefit is an improved urinary flow. This mechanism is typically employed when a patient experiences difficulty or strain during urination.

What side effects are possible with Maxipass?

Possible Side Effects and Safety Information

Maxipass (Tamsulosin Hydrochloride) is a selective alpha-blocker whose safety profile is defined by officially documented adverse reactions classified by frequency and grouped by System-Organ Class (SOC) in regulatory documents (e.g., FDA, EMA SmPC).

Officially Classified Adverse Reactions

Frequency	System-Organ Class	Examples of Documented Adverse Reactions
Common (≥1/100 to <1/10)	Nervous System, Reproductive System	Dizziness, Headache, Abnormal Ejaculation, Rhinitis, Asthenia
Uncommon (≥1/1,000 to <1/100)	Vascular, Gastrointestinal, Skin	Orthostatic Hypotension, Palpitations, Nausea, Vomiting, Rash, Pruritus
Rare (≥1/10,000 to <1/1,000)	Nervous System	Syncope (fainting)
Very Rare (<1/10,000)	Skin, Reproductive System	Stevens-Johnson syndrome, Angioedema, Priapism

Serious Adverse Reactions and Safety Constraints

Regulatory documents list certain rare but clinically significant events. Syncope (fainting), severe cutaneous reactions like Stevens-Johnson syndrome, and urological reactions such as Priapism (a persistent erection) are documented serious adverse reactions. Post-marketing reports also note Intraoperative Floppy Iris Syndrome (IFIS), which has been observed during cataract and glaucoma surgery in patients taking or previously treated with Maxipass.

The medicine is contraindicated in patients with severe hepatic insufficiency. Furthermore, the co-administration with other alpha-adrenergic blocking agents is a contraindication. Caution is advised regarding the use of strong inhibitors of certain liver enzymes (CYP3A4) and the co-administration with Phosphodiesterase-5 (PDE5) inhibitors due to the potential for symptomatic hypotension. Signs and symptoms of orthostasis, such as dizziness or a drop in blood pressure upon standing, are recognized safety patterns observed more frequently during treatment.

Overdose and Emergency Response

Overdose and when to seek help

A suspected overdose of Maxipass (Tamsulosin Hydrochloride) constitutes a serious event that requires immediate emergency medical attention. Official regulatory documents consistently state that the primary clinical manifestation of an overdose is profound hypotension, or severely low blood pressure. This severe cardiovascular effect is a direct result of the drug's pharmacological classification and carries a documented risk of leading to serious outcomes, including syncope (temporary loss of consciousness).

Regulatory guidance mandates that any individual with a known or suspected Maxipass overdose must seek emergency medical assistance immediately. The treating team is guided by the fact that no specific chemical antidote is known. Management, therefore, centers on symptomatic and supportive treatment.

The established procedures documented in prescribing information prioritize stabilization, often starting with placing the individual in a supine position to aid in restoring blood pressure. If this physical measure is insufficient, official labeling recommends considering the administration of intravenous fluids, and in specific cases of persistent, severe hypotension, the use of vasopressors may be necessary. Additionally, regulatory documents require the continuous monitoring of renal function throughout the management period until stabilization is achieved. It is also noted that due to extensive protein binding, removal of the drug through dialysis is unlikely to be effective.

Therapeutic Uses of Maxipass

Maxipass: Main Uses and Therapeutic Benefits

Maxipass is a medication primarily used for managing symptoms arising from various common conditions. The role of this drug is considered relevant in easing symptoms related to physical discomfort and inflammatory or irritative states, as it is used to provide analgesic, anti-inflammatory, and antipyretic support. Medications within this therapeutic class are used for treating symptoms associated with pain, fever, and inflammation. Maxipass is commonly used to help with alleviating symptoms that interfere with daily comfort, including headaches, muscle aches, menstrual cramps, swelling, tenderness, and fever.

The medication is relevant for easing discomfort in clinical scenarios involving acute or unstable symptom patterns. It plays a role in managing symptoms that interfere with daily comfort. This may provide supportive relief, assisting with maintaining functional stability during both acute (short-term) episodes and periods of chronic management, where easing the symptom load may help support general well-being during symptomatic phases.

Universal Context: Relevant for Easing Discomfort

Regulatory References

NIH StatPearls on NSAIDs

Eligibility and Restrictions for Use

Who can and cannot use Maxipass? — Official Regulatory Information

The eligibility profile for Maxipass is officially defined by regulatory documents that strictly determine the permitted population and list formal contraindications for use. The medicine is generally established for use in adult patients who do not possess any excluding conditions listed in the labeling.

Eligibility Scope

Classification	Eligibility Statement (Regulatory Basis)
Populations for whom use is allowed	Adults 18 years of age and older.
Populations for whom use is contraindicated	Patients with a documented hypersensitivity to the active substance or any excipients. Use is prohibited in patients with severe kidney disease (renal impairment) or severe hepatic impairment.
Age-related eligibility rules	Use in pediatric patients (under 18 years) is not established and is typically not recommended. Older adults may require special consideration due to increased sensitivity.
Pregnancy and lactation eligibility status	Contraindicated during pregnancy due to potential serious risk to the unborn baby. Use is unsafe and not recommended during breastfeeding as the drug may pass into breast milk.

Eligibility-Related Restrictions

Use of Maxipass requires special consideration or is restricted in patients with moderate liver disease or certain degrees of kidney function impairment; in these populations, use may be limited or require specific dose adjustments as directed by the official label. The highest level of restriction is Contraindicated, which applies to groups where the risks clearly outweigh any potential benefit.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Maxipass (Atorvastatin) may interact with a variety of other medicines, which can significantly change its level in the body or increase the risk of side effects. These interactions are primarily classified by their effect on drug metabolism or their combined effect on muscle health.

Clinically Significant Interactions

Interacting Product Category	Key Constraint and Regulatory Basis
Strong CYP3A4 Inhibitors (e.g., Clarithromycin, Itraconazole, certain HIV/HCV protease inhibitors)	Combination with certain strong inhibitors (e.g., Cyclosporine, Tipranavir plus Ritonavir) is avoided. Maximum dose limitations apply for co-administration with other inhibitors.
Other Lipid-Modifying Agents (Fibrates, high-dose Niacin)	Co-administration increases the risk of severe skeletal muscle effects (myopathy/rhabdomyolysis) and requires caution.
CYP3A4 Inducers (e.g., Rifampin)	These medicines can lower the level of Maxipass in the body; simultaneous administration is required for Rifampin to ensure effectiveness.
Oral Contraceptives and Digoxin	Maxipass can increase the levels of these co-administered medicines, requiring appropriate monitoring for adjustment of their dosage.

These constraints establish that co-administration with other lipid-modifying agents requires vigilance due to an increased safety risk. Interactions mediated by the CYP3A4 enzyme, such as with cyclosporine or specific antifungals, necessitate strict avoidance of certain drug combinations or the imposition of specific maximum dose limits for Maxipass.

Mechanism of Action

The pharmacological action of Maxipass is initiated by specific interaction with the autonomic nervous system. The mechanism focuses on modulating smooth muscle tone within the lower urinary tract rather than altering tissue structure.

Selective Alpha-1 Receptor Antagonism

Maxipass functions as a selective antagonist (blocker) primarily targeting the alpha-1 (alpha1) adrenergic receptors, specifically the alpha1A and alpha1D subtypes. These receptors are located in the smooth muscle of the prostate gland and bladder neck. This molecular interference prevents the binding of the sympathetic neurotransmitter Norepinephrine, which normally triggers the signal for smooth muscle contraction.

Physiological Smooth Muscle Relaxation

By suppressing the sympathetic signal, Maxipass initiates a key mechanistic cascade that modifies the early molecular steps of the contraction process. This results in the physiological relaxation of the muscle fibers surrounding the urinary passage. This mechanism modulates baseline tissue tone by reducing the level of muscular tension—known as the dynamic component of resistance—which mechanically lowers the internal pressure and resistance to flow.

Dosage and Administration Information

Maxipass is an oral medication with a distinct administration pattern dictated by its formulation as a modified-release capsule of Tamsulosin Hydrochloride. The usage protocol is designed to ensure the slow, consistent release of the active ingredient over a 24-hour period, which necessitates specific timing and handling instructions.

Official Administration Guidelines

Instruction	Detail
Route of administration	Oral route only.
Dosing schedule	The standard regimen begins at 0.4 mg once daily. The dose may be increased to a maximum of 0.8 mg once daily if the initial response is insufficient after two to four weeks.
Timing in relation to meals	Must be taken approximately one-half hour following the same meal each day to promote consistent absorption.

Procedural and Population Rules

To maintain the intended release profile of the modified-release capsule, the medication must be swallowed whole with water. The capsules must not be crushed, chewed, broken, or opened. If a dose is missed, the next dose should not be doubled to compensate. If treatment is interrupted for several days, it must be restarted at the lower 0.4 mg once-daily dose.

Regarding specific patient groups, no dose adjustment is required for patients with mild to moderate renal or hepatic impairment. Maxipass is not indicated for use in pediatric populations.

Recent Clinical Evidence

Research evidence / Overview of studies for Maxipass

Evidence for Use in Lower Urinary Tract Symptoms (LUTS) due to BPH

Research examined Maxipass in patients presenting with Lower Urinary Tract Symptoms (LUTS) related to Benign Prostatic Hyperplasia (BPH). This primary evidence base consists of large-scale Randomized Controlled Trials (RCTs), which compared the medicine to an inactive substance (placebo). These trials was evaluated in adult men experiencing conditions characterized by fluctuating or episodic manifestations of LUTS, such as problems with frequency, urgency, or weak stream.

In these controlled settings, research examined whether there were changes measured during the study period in symptoms. Studies monitored patient-reported outcomes describing perceived discomfort using formal questionnaires, like the International Prostate Symptom Score (I-PSS). They also examined objective functional measures, such as the Peak Urinary Flow Rate and the amount of urine remaining after voiding (Post-Void Residual volume). Studies reported patterns observed over short-term intervals (typically a few months).

Long-Term Evidence and Durability of Observation

Evidence on the maintenance of observed measurements over time comes primarily from long-term open-label follow-up studies rather than controlled trials. These studies was observed in participants for several years. The research explored whether the initial measurements of symptom change and functional flow rate were sustained during these extended observation periods. The data from these long-term settings indicate patterns related to measurements taken over time, but comparative evidence against a non-active control is limited in the long-term context.

What is Still Uncertain About Maxipass Research

A review of the evidence highlights several areas where research is ongoing or where data remain insufficient. One key limitation is the absence of long-term placebo-controlled data, as most controlled trials focus on short-term outcomes. Research examined how findings relate to certain subgroups, such as older adults or those with diabetes, but data for some less-common groups remain insufficient. The available studies provide context but not individual predictions, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

Label: TAMSULOSIN HYDROCHLORIDE capsule (Official FDA/DailyMed Monograph)

Frequently Asked Questions (FAQ)

Common questions about Maxipass (FAQ)

Q: How long until I feel the effects of tamsulosin?

Official product information suggests that Maxipass (Tamsulosin) typically takes time to build up to a consistent level in the body. The drug generally reaches what is called steady-state concentration (a consistent level of the medicine in the bloodstream) after approximately five days of taking a regular daily dose. This time frame is generally when the amount of medicine entering the body is balanced with the amount leaving it.

Q: Is it safe to take tamsulosin for an enlarged prostate if I have low blood pressure?

Regulatory documents state that patients may experience symptoms related to postural hypotension (a drop in blood pressure when changing positions, such as standing up). These effects can include lightheadedness, dizziness, or fainting. The official warnings caution individuals about the potential for these episodes and suggest awareness to mitigate risks that could result from fainting.

Q: Is it safe to drink alcohol while taking tamsulosin?

The official product information indicates that the concurrent use of alcohol may increase the risk of experiencing orthostatic hypotension (a drop in blood pressure when changing position). This effect may cause symptoms such as dizziness, lightheadedness, or syncope (fainting).

How should Maxipass be stored and disposed of?

Storage and Disposal Requirements

Maxipass (Tamsulosin Hydrochloride) must be stored strictly according to the conditions detailed in the official regulatory labeling.

Storage & Disposal Scope
Temperature Requirements: Store at controlled room temperature, typically 20 C to 25 C, with excursions permitted. Keep from freezing and excessive heat.
Protection and Handling: The container must be kept tightly closed and stored in a dry place away from moisture. The modified-release capsules must not be crushed, chewed, or opened.
Child Safety: The product must be stored out of the reach and sight of children and pets at all times, secured with a locked safety cap.
Disposal Instructions: Unused or expired medication should be disposed of via an authorized drug take-back program. If a take-back option is unavailable, the medicine must be mixed with an unappealing substance (like dirt or cat litter), sealed in a bag, and discarded in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Bangladesh

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z